Company: PTPI
Filing Date: 2025-02-14
Form Type: S-1/A
Source: 0001410578-25-000137
Chunk: 5

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-14
Form: S-1/A
Chunk 5
---
 may not be indicative of the actual public offering price for our Units. There is no established public trading market for each of the Series Warrants or the Pre-Funded Warrants, and we do not expect a market to develop. In addition, we do not intend to apply for the listing of either of the Series Warrants or the Pre-Funded Warrants on any national securities exchange. Without an active trading market, the liquidity of the Series Warrants and the Pre-Funded Warrants will be limited.

We will have one closing for all the securities purchased in this offering. The public offering price per Unit will be fixed for the duration of this offering.

This offering will terminate on , 2025, unless we decide to terminate the offering (which we may do at any time in our discretion) prior to such date. We will have one closing for all the securities purchased in this offering. The public offering price per Unit will be fixed for the duration of this offering.

We may sell fewer than all securities offered hereby, which may significantly reduce the amount of proceeds received by us, and investors in this offering will not receive a refund if we do not sell all of the securities offered hereby. We have not established an escrow account in conjunction with this offering. Because there is no escrow account and no minimum number of securities or amount of proceeds, investors could be in a position where they have invested in us, but we have not raised sufficient proceeds in this offering to adequately fund the intended uses of the proceeds as described in this prospectus.

|                                     |   | Per                       
 Share of Common Stock and 
 Series Warrants           |     |   | Per Pre-Funded  
 Warrant and     
 Series Warrants |     |   | Total |     |   |
|:------------------------------------|:--|:--------------------------|:----|:--|:----------------|:----|:--|:------|:----|:--|
| Public offering price               | ​ | $                         |     | ​ | $               |     | ​ | $     |     | ​ |
| Placement Agent fees(1)             | ​ | ​                         |     | ​ | ​               |     | ​ | ​     |     | ​ |
| Proceeds, before expenses, to us(2) | ​ | $                         |     | ​ | $               |     | ​ | $     |     | ​ |

(1)We have agreed to pay Dawson James a total cash fee equal to 8% of the aggregate gross